Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Report Format: PDF+Excel | Report ID: SR112023A7343
Buy Now

The neuromyelitis optica market has been comprehensively analyzed in IMARC's new report titled "Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033". Neuromyelitis optica refers to a rare autoimmune disease affecting the central nervous system, specifically the optic nerves and spinal cord. In this case, the immune system attacks the myelin sheath that protects the nerve fibers, leading to inflammation, demyelination, and nerve damage. The common indications of the ailment include weakness or numbness in the arms and legs, pain in the eyes, loss of vision, paralysis of the legs and arms, difficulty controlling the bladder or bowels, etc. Individuals suffering from neuromyelitis optica may also experience confusion, spasticity, sexual dysfunction, hearing loss, uncontrollable hiccups or itching, vertigo, etc. The diagnosis of this condition is based on a review of the patient's symptoms, along with a neurological and physical exam. Several diagnostic imaging studies are utilized to identify lesions in the spinal cord and optic nerves that are characteristic of the ailment. Additionally, various laboratory tests are performed to detect the presence of antibodies that target a protein called aquaporin-4 (AQP4), which are present in most patients. In some cases, a spinal tap (lumbar puncture) is also done to analyze the cerebrospinal fluid for signs of inflammation.

The rising cases of autoimmune disorders, which cause the body's defense system to attack healthy cells by defect, are primarily driving the neuromyelitis optica market. In addition to this, the escalating prevalence of various risk factors, such as vitamin D deficiency, chain smoking, gastrointestinal infections, etc., is also bolstering the market growth. Furthermore, the widespread adoption of immunosuppressive drugs, including mycophenolate mofetil and rituximab, for treating the disease is acting as another significant growth-inducing factor. These agents mainly target T and B cell functions to eliminate proinflammatory molecules from the peripheral bloodstream and prevent attacks. Additionally, several key players are making extensive investments in R&D activities to launch novel technologies that facilitate an improved understanding of the immunopathological mechanisms underlying the illness. This, in turn, is creating a positive outlook for the market. Moreover, the emerging popularity of monoclonal antibodies, such as anti-CD19 and anti-interleukin-6, owing to their numerous advantages, including enhanced safety, lower toxicity, and improved patient outcomes, is further expected to drive the neuromyelitis optica market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuromyelitis optica market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuromyelitis optica and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuromyelitis optica market in any manner.

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the neuromyelitis optica market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the neuromyelitis optica market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs
     

This report also provides a detailed analysis of the current neuromyelitis optica marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
        

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Key Questions Answered in this Report

Market Insights

  • How has the neuromyelitis optica market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the neuromyelitis optica market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the neuromyelitis optica market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2017-2033) of neuromyelitis optica across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of neuromyelitis optica by age across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of neuromyelitis optica by gender across the seven major markets?
  • How many patients are diagnosed (2017-2033) with neuromyelitis optica across the seven major markets?
  • What is the size of the neuromyelitis optica patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of neuromyelitis optica?
  • What will be the growth rate of patients across the seven major markets?
     

Neuromyelitis Optica: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for neuromyelitis optica drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuromyelitis optica market?
  • What are the key regulatory events related to the neuromyelitis optica market?
  • What is the structure of clinical trial landscape by status related to the neuromyelitis optica market?
  • What is the structure of clinical trial landscape by phase related to the neuromyelitis optica market?
  • What is the structure of clinical trial landscape by route of administration related to the neuromyelitis optica market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Neuromyelitis Optica Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033
Select License Type



Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More